Olema Pharmaceuticals (NASDAQ:OLMA) Director Cyrus Harmon Sells 12,500 Shares

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon sold 12,500 shares of the firm’s stock in a transaction dated Thursday, July 23rd. The shares were sold at an average price of $11.58, for a total transaction of $144,750.00. Following the transaction, the director directly owned 715,270 shares in the company, valued at approximately $8,282,826.60. The trade was a 1.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Olema Pharmaceuticals Stock Down 3.2%

OLMA stock opened at $11.62 on Wednesday. The firm’s 50-day moving average is $11.56 and its two-hundred day moving average is $16.79. The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of -5.75 and a beta of 2.00. Olema Pharmaceuticals, Inc. has a 52 week low of $4.47 and a 52 week high of $36.26. The company has a current ratio of 10.88, a quick ratio of 10.88 and a debt-to-equity ratio of 0.01.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.52). On average, analysts forecast that Olema Pharmaceuticals, Inc. will post -2.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research report on Friday, July 17th. Wall Street Zen lowered Olema Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday. Guggenheim decreased their target price on Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Olema Pharmaceuticals in a report on Friday, May 22nd. Eleven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Olema Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $44.10.

Institutional Trading of Olema Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC boosted its holdings in Olema Pharmaceuticals by 9,476.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock worth $31,000 after buying an additional 1,232 shares in the last quarter. Torren Management LLC bought a new position in shares of Olema Pharmaceuticals in the fourth quarter valued at $44,000. Russell Investments Group Ltd. bought a new position in shares of Olema Pharmaceuticals in the third quarter valued at $53,000. American Century Companies Inc. acquired a new stake in shares of Olema Pharmaceuticals during the 2nd quarter valued at $54,000. Finally, Creative Planning acquired a new stake in shares of Olema Pharmaceuticals during the 2nd quarter valued at $83,000. 91.78% of the stock is owned by institutional investors and hedge funds.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.